Valley National Advisers Inc Amgen Inc Transaction History

Valley National Advisers Inc

$554 Million
Q3 2024

A detailed history of Valley National Advisers Inc transactions in Amgen Inc stock. As of the latest transaction made, Valley National Advisers Inc holds 13,534 shares of AMGN stock, worth $3.57 Million. This represents 0.79% of its overall portfolio holdings.

Number of Shares

13,534

Previous 23,634 42.74%

Holding current value

$3.57 Million

Previous $7.38 Million 40.95%

% of portfolio

0.79%

Previous 1.1%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 24, 2024	SELL	$309.38 - $337.38 $3.12 Million - $3.41 Million	-10,100 Reduced 42.74%	13,534 $4.36 Million
Q2 2024 Jul 18, 2024	SELL	$262.75 - $319.31 $244,883 - $297,596	-932 Reduced 3.79%	23,634 $7.38 Million
Q1 2024 Apr 19, 2024	SELL	$268.87 - $324.56 $155,406 - $187,595	-578 Reduced 2.3%	24,566 $6.98 Million
Q4 2023 Jan 25, 2024	SELL	$255.7 - $288.46 $303,771 - $342,690	-1,188 Reduced 4.51%	25,144 $7.24 Million
Q3 2023 Nov 13, 2023	SELL	$218.65 - $271.46 $72,810 - $90,396	-333 Reduced 1.25%	26,332 $7.08 Million
Q2 2023 Jul 31, 2023	SELL	$214.27 - $253.37 $4,713 - $5,574	-22 Reduced 0.08%	26,665 $5.92 Million
Q1 2023 Apr 26, 2023	SELL	$225.79 - $275.2 $48,093 - $58,617	-213 Reduced 0.79%	26,687 $6.52 Million
Q4 2022 Jan 12, 2023	SELL	$229.03 - $291.01 $166,275 - $211,273	-726 Reduced 2.63%	26,900 $7.34 Million
Q3 2022 Nov 08, 2022	BUY	$224.46 - $253.15 $166,549 - $187,837	742 Added 2.76%	27,626 $6.97 Million
Q2 2022 Jul 15, 2022	BUY	$230.71 - $256.74 $28,146 - $31,322	122 Added 0.46%	26,884 $6.65 Million
Q1 2022 May 06, 2022	BUY	$219.27 - $242.57 $80,472 - $89,023	367 Added 1.39%	26,762 $6.47 Million
Q4 2021 Feb 11, 2022	SELL	$198.88 - $227.6 $98,644 - $112,889	-496 Reduced 1.84%	26,395 $5.94 Million
Q3 2021 Nov 10, 2021	SELL	$212.27 - $248.7 $72,596 - $85,055	-342 Reduced 1.26%	26,891 $5.72 Million
Q2 2021 Aug 02, 2021	SELL	$233.58 - $259.14 $40,175 - $44,572	-172 Reduced 0.63%	27,233 $6.64 Million
Q1 2021 May 07, 2021	SELL	$221.91 - $258.6 $126,266 - $147,143	-569 Reduced 2.03%	27,405 $6.82 Million
Q4 2020 Feb 11, 2021	SELL	$216.38 - $257.67 $223,304 - $265,915	-1,032 Reduced 3.56%	27,974 $6.43 Million
Q3 2020 Nov 13, 2020	SELL	$234.65 - $260.95 $260,226 - $289,393	-1,109 Reduced 3.68%	29,006 $7.37 Million
Q2 2020 Aug 10, 2020	SELL	$197.81 - $242.74 $266,647 - $327,213	-1,348 Reduced 4.28%	30,115 $7.1 Million
Q1 2020 May 13, 2020	SELL	$182.24 - $241.7 $302,518 - $401,222	-1,660 Reduced 5.01%	31,463 $6.38 Million
Q4 2019 Feb 13, 2020	BUY	$189.21 - $243.2 $97,443 - $125,248	515 Added 1.58%	33,123 $7.99 Million
Q3 2019 Nov 12, 2019	BUY	$174.11 - $208.62 $538,174 - $644,844	3,091 Added 10.47%	32,608 $6.31 Million
Q2 2019 Aug 08, 2019	BUY	$166.7 - $195.41 $399,913 - $468,788	2,399 Added 8.85%	29,517 $5.44 Million
Q1 2019 Apr 26, 2019	BUY	$180.87 - $203.88 $95,861 - $108,056	530 Added 1.99%	27,118 $5.15 Million
Q4 2018 Feb 25, 2019	BUY	$178.4 - $208.25 $167,874 - $195,963	941 Added 3.67%	26,588 $5.18 Million
Q3 2018 Nov 08, 2018	BUY	$185.29 - $208.89 $216,233 - $243,774	1,167 Added 4.77%	25,647 $5.32 Million
Q2 2018 Aug 14, 2018	BUY	$166.05 - $186.51 $234,794 - $263,725	1,414 Added 6.13%	24,480 $4.52 Million
Q1 2018 Apr 19, 2018	BUY	$169.43 - $198.0 $718,552 - $839,718	4,241 Added 22.53%	23,066 $3.93 Million
Q4 2017 Feb 13, 2018	BUY	$168.79 - $188.59 $949,781 - $1.06 Million	5,627 Added 42.64%	18,825 $3.27 Million
Q3 2017 Nov 14, 2017	BUY	$167.29 - $191.0 $2.21 Million - $2.52 Million	13,198	13,198 $2.46 Million

Others Institutions Holding AMGN

# of Institutions

3,125

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $141B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Valley National Advisers Inc, based on Form 13F filings with the SEC.

News

Stay updated on Valley National Advisers Inc with notifications on news.

Account

Valley National Advisers Inc Amgen Inc Transaction History